Global Rank
#33253
Country Rank
#4339
Market Cap
29.3 M
Price
2
Change (%)
4.76%
Volume
404
Eagle Pharmaceuticals's latest marketcap:
29.3 M
As of 06/08/2025, Eagle Pharmaceuticals's market capitalization has reached $29.3 M. According to our data, Eagle Pharmaceuticals is the 33253th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 29.3 M |
| Revenue (ttm) | 257.55 M |
| Net Income (ttm) | 11.95 M |
| Shares Out | 13.02 M |
| EPS (ttm) | 0.91 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 03/07/2025 |
Market Cap Chart
Data Updated: 06/08/2025
Eagle Pharmaceuticals's yearly market capitalization.
Eagle Pharmaceuticals has seen its market value drop from $606.81 M to $29.3 M since 2020, representing a total decrease of 95.17% and an annual compound decline rate (CAGR) of 49.49%.
| Date | Market Cap | Change (%) |
|---|---|---|
| 06/08/2025 | $29.3 M | 350% |
| 12/31/2024 | $6.51 M | -90.41% |
| 12/29/2023 | $67.92 M | -82.15% |
| 12/30/2022 | $380.45 M | -42.14% |
| 12/31/2021 | $657.57 M | 8.37% |
| 12/31/2020 | $606.81 M |
Company Profile
About Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc. is a pharmaceutical company dedicated to developing and commercializing innovative treatments for critical care and oncology patients in the United States.
Key Products
- Ryanodex – For malignant hyperthermia
- Belrapzo & Bendeka – For chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma
Product Pipeline
- EP-4104 – A dantrolene sodium treatment for organophosphate exposure
- PEMFEXY – A ready-to-use liquid pemetrexed for non-small cell lung cancer and mesothelioma
- EA-114 (fulvestrant) – For HR+/HER2- breast cancer
- Vasopressin injection – To enhance blood pressure in vasodilatory shock
Strategic Collaborations
- License agreement with Combioxin, SA for CAL02, an antitoxin agent for severe pneumonia
- Partnership with AOP Orphan Pharmaceuticals GmbH for Landiolol, a treatment for supraventricular tachycardia
- Collaboration with Tyme Technologies, Inc. for SM-88 in breast cancer and metastatic sarcomas
Founded in 2007, Eagle Pharmaceuticals is headquartered in Woodcliff Lake, New Jersey.
Frequently Asked Questions
-
What is Eagle Pharmaceuticals's (OTC-EGRX) current market cap?As of 06/08/2025, Eagle Pharmaceuticals (including the parent company, if applicable) has an estimated market capitalization of $29.3 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Eagle Pharmaceuticals (OTC-EGRX) rank globally by market cap?Eagle Pharmaceuticals global market capitalization ranking is approximately 33253 as of 06/08/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.